Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272704 | 0.82 | ALOX5 (0.44) | PRKDCPOLBL3MBTL1LCKFYN | |
| SCHEMBL5852202 | 0.82 | ALOX5 (0.44) | POLBL3MBTL1LCKFYNALOX5 | |
| SCHEMBL29878552 | 0.81 | POLB (0.67) | PRKDCPOLBL3MBTL1LCKFYN | |
| SCHEMBL369991 | 0.81 | POLB (0.67) | PRKDCPOLBL3MBTL1LCKFYN | |
| SCHEMBL30202128 | 0.76 | POLB (0.54) | PRKDCPOLBL3MBTL1LCKFYN | |
| SCHEMBL5181298 | 0.76 | CYP3A4 (0.43) | MAPTHTR2ACYP3A4ALDH1A1GRIN2D | |
| SCHEMBL580565 | 0.76 | POLB (0.54) | PRKDCPOLBL3MBTL1LCKFYN | |
| SCHEMBL10717601 | 0.75 | CYP3A4 (0.41) | POLBL3MBTL1MAPTPTGS2CYP3A4 | |
| SCHEMBL298224 | 0.75 | POLB (0.59) | PRKDCPOLBL3MBTL1MAPTNPSR1 | |
| SCHEMBL19297778 | 0.75 | HTR7 (0.44) | L3MBTL1MAPTNPSR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | claimed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | claimed |
| CN-1950342-A | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-04-18 | — | — | CN | claimed |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| CN-104650005-B | A kind of synthetic method of Pinaverium Bromide | 北京万生药业有限责任公司 | 2018-10-12 | — | — | CN | disclosed |
| CN-106977523-A | FSHR antagonists with phenyl and nafoxidine structure and preparation method thereof | 河南师范大学 | 2017-07-25 | — | — | CN | disclosed |
| EP-1389216-B1 | AVERMECTINS SUBSTITUTED IN THE 4\"-POSITION HAVING PESTICIDAL PROPERTIES | MERIAL INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | disclosed |
| EP-2653465-B1 | Opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2573068-B9 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2573068-B1 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2298744-B1 | Opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2573068-A1 | Process for preparing intermediates of compounds useful as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2013-03-27 | — | — | EP | disclosed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2298744-A2 | Opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-7732416-B2 | For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection | MERIAL LIMITED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060105970-A1 | Avermectins substituted in the 4\"-position having pesticidal properties | SYNGENTA CROP PROTECTION, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105970-A1 | Avermectins substituted in the 4\"-position having pesticidal properties | DDT, C3AR1, C9 | PRKDC 4493/4885POLB 4473/4885L3MBTL1 78/4885 |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | PRKDC 1804/4885POLB 383/4885L3MBTL1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.